Effects of oral magnesium and vitamin d co-supplementation on glycemic control in type 2 diabetes mellitus: a double-blinded, randomized, control trial

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230707008

Enrollment

200

Registered

2023-07-07

Start date

2023-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus with hemoglobinA1C 7.5-9% Type 2 Diabetes Mellitus Noninsulin-Dependent Diabetes Mellitus Diabetes Mellitus, Noninsulin-Dependent Diabetes, Type 2 Diabetes Mellitus, Adult-Onset

Interventions

Oral magnesium oxide 1 tab tid with oral vitamin D2 20,000 IU weekly,Oral magnesium oxide 1 tab tid with placebo of vitamin D2 20,000 IU weekly,Placebo of oral magnesium oxide 1 tab tid with vitamin D

Experimental Drug,Active Comparator Drug,Active Comparator Drug,Placebo Comparator Drug

VitaminD-OralMagnesium,Magnesium-Placebo,Placebo-Vitamin D,Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: > 18 years of age of Type 2 diabetes mellitus with hemoglobin A1C 7.5-9%

Exclusion criteria

Exclusion criteria: Currently use of oral magnesium or vitamin D Diuretics use within 4 weeks Pregnancy Chronic kidney disease (eGFR<45) Chronic diarrhea Active cardiac condition Active malignancy Hypercalcemia

Design outcomes

Primary

Measure	Time frame
HemoglobinA1C 12 weeks Mean difference	—

Secondary

Measure	Time frame
HOMA-IR 12 weeks Mean difference,FBS 12 weeks Mean difference,Vitamin D level 12 weeks Mean difference,Serum magnesium level 12 weeks Mean difference	—

Countries

Thailand

Contacts

Public ContactNuttaya Wachiraphansakul

Lampang Hospital

iewnuttaya@gmail.com0818868085

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026